CLDX Celldex Therapeutics Inc

Price (delayed)

$17.53

Market cap

$693.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.18

Enterprise value

$679.27M

Sector: Healthcare
Industry: Biotechnology

Highlights

CLDX's EPS is up by 35% YoY and by 15% from the previous quarter
The company's gross profit rose by 2.8% QoQ
CLDX's quick ratio has surged by 165% year-on-year but it is down by 14% since the previous quarter
Celldex Therapeutics's equity has soared by 127% YoY but it has decreased by 3.6% from the previous quarter
The debt has increased by 25% QoQ

Key stats

What are the main financial stats of CLDX
Market
Shares outstanding
39.57M
Market cap
$693.61M
Enterprise value
$679.27M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.98
Price to sales (P/S)
152.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
150.31
Earnings
Revenue
$4.52M
EBIT
-$48.56M
EBITDA
-$44.24M
Free cash flow
-$47.6M
Per share
EPS
-$2.18
Free cash flow per share
-$1.21
Book value per share
$5.88
Revenue per share
$0.12
TBVPS
$5.36
Balance sheet
Total assets
$255.77M
Total liabilities
$25.8M
Debt
$3.81M
Equity
$229.98M
Working capital
$190.73M
Liquidity
Debt to equity
0.02
Current ratio
16.63
Quick ratio
16.43
Net debt/EBITDA
0.32
Margins
EBITDA margin
-978.9%
Gross margin
100%
Net margin
-1,069.4%
Operating margin
-1,227.7%
Efficiency
Return on assets
-25.7%
Return on equity
-29.9%
Return on invested capital
-47%
Return on capital employed
-19.9%
Return on sales
-1,074.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLDX stock price

How has the Celldex Therapeutics stock price performed over time
Intraday
-2.5%
1 week
0%
1 month
-0.4%
1 year
604.02%
YTD
0.06%
QTD
0.06%

Financial performance

How have Celldex Therapeutics's revenue and profit performed over time
Revenue
$4.52M
Gross profit
$4.52M
Operating income
-$55.48M
Net income
-$48.33M
Gross margin
100%
Net margin
-1,069.4%
Celldex Therapeutics's net income has decreased by 6% from the previous quarter but it has increased by 3% YoY
CLDX's operating margin is up by 4.9% year-on-year and by 3.2% since the previous quarter
The net margin has increased by 4.5% YoY but it has decreased by 3.3% QoQ
Celldex Therapeutics's operating income has increased by 3.4% YoY

Growth

What is Celldex Therapeutics's growth rate over time

Valuation

What is Celldex Therapeutics stock price valuation
P/E
N/A
P/B
2.98
P/S
152.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
150.31
CLDX's EPS is up by 35% YoY and by 15% from the previous quarter
The P/B is 171% higher than the last 4 quarters average of 1.1 and 148% higher than the 5-year quarterly average of 1.2
Celldex Therapeutics's equity has soared by 127% YoY but it has decreased by 3.6% from the previous quarter
CLDX's price to sales (P/S) is 191% higher than its last 4 quarters average of 52.3
Celldex Therapeutics's revenue has increased by 2.8% from the previous quarter

Efficiency

How efficient is Celldex Therapeutics business performance
Celldex Therapeutics's ROIC has increased by 40% YoY and by 26% from the previous quarter
The ROE has grown by 33% YoY and by 15% from the previous quarter
The ROA is up by 26% YoY and by 11% QoQ
CLDX's ROS is up by 4.1% YoY but it is down by 3.3% from the previous quarter

Dividends

What is CLDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLDX.

Financial health

How did Celldex Therapeutics financials performed over time
CLDX's quick ratio has surged by 165% year-on-year but it is down by 14% since the previous quarter
The current ratio has soared by 163% YoY but it has decreased by 14% from the previous quarter
The debt is 98% lower than the equity
Celldex Therapeutics's equity has soared by 127% YoY but it has decreased by 3.6% from the previous quarter
CLDX's debt to equity has surged by 100% since the previous quarter but it has dropped by 50% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.